apact study of Abraxane + gemcitabine following surgical resection for pancreatic cancer failed to achieve primary endpoint

The Celgene-sponsored, pivotal, Phase III apact study evaluating the investigational use of Abraxanein combination with gemcitabine following surgical resection (adjuvant treatment) in patients with pancreatic cancer did not achieve the primary endpoint of improvement in disease-free survival, as confirmed by independent radiological review, compared to gemcitabine alone.

Overall survival, a secondary endpoint of the study, was improved, reaching nominal statistical significance, with Abraxane in combination with gemcitabine compared to gemcitabine alone. The safety profile observed in the apact study was consistent with previously reported studies of Abraxane. Data from apact will be submitted to a future medical meeting.